Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Steroid Receptor Agonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Steroid hormone receptors are generally intracellular receptors, which initiate signal transduction for steroid hormones such as glucocorticoid and mineralocorticoid, which lead to changes in gene expression. Steroid receptor agonists show their effects by decreasing vasodilation and permeability of capillaries, as well as decreasing leukocyte migration sites of inflammation. They also inhibit neutrophil apoptosis and demargination, the inhibition of phospholipase A2, decreases the formation of arachidonic acid derivatives. Additionally, they inhibit NF-Kappa B and other inflammatory transcription factors, they also promote anti-inflammatory genes like interleukin-10. Steroid receptor agonists are indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant. AbbVie, Pfizer, Ocular Therapeutix, Novartis, Bayer, and EyePoint Pharma are some of the major players in the steroid receptor agonists market.
Key Market Developments:
Approved Drug Molecules and Brand Names for Steroid Receptor Agonists:
Drugs under the Pipeline for Steroid Receptor Agonists:
Clinical Activity and Developments of Steroid Receptor Agonists:
Currently, there are about 59 drug products in steroid receptor agonists, including more than 30 approved ones, and other drug molecules are in clinical trial phases.
Molecule Name |
Number of Studies |
Airsupra (Budesonide/Salbutamol) |
8 |
Dexamethasone ophthalmic (EGP-437) |
7 |
Bexarotene/Betamethasone dipropionate (LAS 41004) |
6 |
Captisol-enabled Budesonide |
5 |
DexaSite (Dexamethasone 0.1% in DuraSite) |
3 |
Synbitide HFA MDI (Budesonide/Procaterol) |
3 |
Clobetasol nanosuspension (APP13007) |
3 |
Clobetasol propionate ophthalmic nanoemulsion 0.05% (SVT-15473) |
3 |
orBec (Beclomethasone dipropionate oral) |
3 |
Betamethasone/Calcipotriol (BFH 772) |
2 |
Cortiject (Dexamethasone palmitate) |
1 |
DSP-Visulex (Dexamethasone sodium phosphate ophthalmic) |
1 |
Rivelin Clobetasol patch (Clobetasol propionate oral) |
1 |
TBS-5 |
1 |
Dexamethasone (IBE-814) |
1 |
Steroid receptor agonists are marketed for the treatment of ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, polymyalgia rheumatica, psoriatic arthritis, rheumatoid arthritis, uveitis, atopic dermatitis, ulcerative colitis, plaque psoriasis, IgA nephropathy, dry eyes, ocular inflammation, ocular pain, allergic conjunctivitis, duchenne muscular dystrophy, and others. Moreover, some of the Steroid receptor agonists are in clinical trial phases for conditions such as diabetic macular edema, meibomianitis, retinal vein occlusion, post-operative inflammation, and pain, Crohn’s disease, radiation injuries, lichen planus, aphthous stomatitis, and others.
Download Free Sample Report
Prednisone, Dexamethasone injection, Ozurdex (Dexamethasone intravitreal implant), Prednisone delayed-release tablet, Calcipotriol/betamethasone dipropionate, Solu-Cortef (Hydrocortisone sodium succinate injection), Clobetasol propionate topical are the few approved steroid receptor agonists.
AbbVie, Pfizer, Ocular Therapeutix, Novartis, Bayer, and EyePoint Pharma are some of the major players in the steroid receptor agonists market.
Major indications for steroid receptor agonists are ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, polymyalgia rheumatica, psoriatic arthritis, rheumatoid arthritis, uveitis, atopic dermatitis, ulcerative colitis, plaque psoriasis, and others.
There are a total of 15 molecules in the phase-I/II clinical development for steroid receptor agonists.
Key Market Players